India


HOLD (no change)

Consensus ratings*: Buy 15 Ho	old 11 Sell 12
Current price:	Rs1,156
Target price:	Rs1,250
Previous target:	Rs1,300
Up/downside:	8.1%
InCred Research / Consensus:	-7.2%
Reuters:	REDY.NS
Bloomberg:	DRRD IN
Market cap:	US\$11,298m
	Rs964,547m
Average daily turnover:	US\$34.2m
	Rs2916.6m
Current shares o/s:	833.5m
Free float: *Source: Bloomberg	73.3%

Key changes in this note

Revise upward our FY26F EPS by 7%.

- Lower our target price to Rs1,250.
- Introduce FY27F estimates.



Major shareholders	% held
Promoters	26.7
LIC	9.7
First State	2.7

Research Analyst(s)

Yogesh SONI T (91) 22 4161 1566 E yogesh.soni@incredresearch.com

Dr Reddy's Laboratories Ltd

Concerns remain over medium-term outlook

- Dr Reddy's Labs posted in-line 4Q revenue growth of 12%, with a miss on the margin front due to higher R&D spending, one-off costs & gross margin hit.
- Aggregate incremental revenue from bDesonumab, bAbatacept bRituximab and Semaglutide may not be able to fill the gRevlimid void in FY27F.
- We raise FY26F EPS by 7%. Our target price stands revised to Rs1,250 (Rs1,300 earlier). We maintain HOLD rating on the stock.

In-line growth in 4QFY25; miss on the margin front

Dr. Reddy's Laboratories or DRL's 4QFY25 performance was mixed – while the topline growth was in line, the margin missed our estimate. In 4Q, the revenue growth was 20%/2% YoY/QoQ, and adjusting for the NRT business (Rs5.97bn) the overall business witnessed a 2% sequential growth. Though US revenue grew sequentially by 2.6% to US\$411m, it was below our estimate of US\$430m which, we believe, was due to price erosion and intense competition in certain products. India business growth in 4Q was 16% YoY, but organic growth (excl. in-licensed product) was weak at 6% YoY. DRL managed to marginally outperform the IPM with a growth of 8.4% vs. 8% IPM growth. Gross margin (GM) declined by 310bp QoQ due to lower milestone income and lower operating leverage. The EBITDA margin stood at 23.2% (below our estimate of 26.5%), a decline of 320bp QoQ (on adjusted basis) due to higher R&D spending (by 50bp), one-off manufacturing overhead costs (impact of 80bp) and lower gross margin impact. DRL has given guidance of double-digit growth in FY26F and maintaining 25% margin. However, we remain cautious of the guidance due to the base effect and bake in 9% growth in FY26F.

The gRevlimid void - difficult for new launches to fill in

In FY25, we believe that gRevlimid would have accounted for 35-40% of the US revenue (US\$550-650m) and estimate that it will contribute US\$450-500m in FY26F. DRL's major launches in FY26F-27F includes the launch of biosimilars (bDesonumab – late FY26F launch, bAbatacept – late FY27F/beginning of FY28F launch, bRituximab – FY26F launch) and the 2026F launch of Semaglutide in Canada and other RoW markets. We understand these launches, in aggregate, may not be able to generate incremental revenue of US\$450-500m in FY27F and bridge the gRevlimid gap once the settlement period ends in Jan 2026. Accordingly, we estimate the US revenue to decline by 20% in FY27F.

Other highlights

a) R&D spending to be 8.5% in FY26F. b) Effective tax rate will be 25% in FY26F. c) SG&A expenses in FY26F to be 28%. d) Capex in FY26F to be similar to the FY25 level.

Retain HOLD rating with a lower target price of Rs1,250

On one-year forward basis, DRL trades below SD-1 valuation however, on two-year forward basis, it trades near the mean valuation (due to 17% EPS dip estimated in FY27F). We believe DRL is fairly valued due to muted earnings outlook for FY27F & retain our HOLD rating on it with a new target price of Rs1,250 (Rs1.300 earlier). Faster-than expected improvement in base business profitability is an upside risk and vice-versa.

Financial Summary	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Revenue (Rsm)	245,879	279,163	325,535	354,680	331,089
Operating EBITDA (Rsm)	63,873	78,384	84,544	90,403	79,097
Net Profit (Rsm)	45,067	55,683	56,545	57,598	47,868
Core EPS (Rs)	54.1	66.8	67.8	69.1	57.4
Core EPS Growth	45.0%	23.6%	1.5%	1.9%	(16.9%)
FD Core P/E (x)	21.38	17.30	17.04	16.73	20.13
DPS (Rs)	70.0	40.0	8.0	8.0	8.0
Dividend Yield	6.06%	3.46%	0.69%	0.69%	0.69%
EV/EBITDA (x)	14.22	11.44	11.12	10.19	10.91
P/FCFE (x)	12.11	13.77	32.06	14.39	7.28
Net Gearing	(21.5%)	(22.0%)	(3.5%)	(7.7%)	(20.4%)
P/BV (x)	4.17	3.43	2.89	2.50	2.26
ROE	21.4%	21.8%	18.4%	16.0%	11.8%
% Change In Core EPS Estimates				7.38%	
InCred Research/Consensus EPS (x)					

SOURCE: INCRED RESEARCH, COMPANY REPORTS

InCred Equities

Pharmaceuticals | India Dr Reddy's Laboratories Ltd | May 12, 2025

(Rsm)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Y-o-Y (%)	Q-o-Q (%)
Revenue	62,968	67,384	68,802	72,148	70,829	76,727	80,162	83,586	85,060	20%	2%
Consumption of raw materials	26,971	27,831	28,434	29,945	29,347	30,383	32,393	34,534	37,797	29%	9%
as % of sales	42.8%	41.3%	41.3%	41.5%	41.4%	39.6%	40.4%	41.3%	44.4%		
R&D expenditure	5366	4984	5447	5565	6877	6193	7271	6658	7258	6%	9%
as % of sales	8.5%	7.4%	7.9%	7.7%	9.7%	8.1%	9.1%	8.0%	8.5%		
Other expenditure	15,501	14,130	15,060	16,568	16,591	18,886	19,956	19,394	20,268	22%	5%
as % of sales	24.6%	21.0%	21.9%	23.0%	23.4%	24.6%	24.9%	23.2%	23.8%		
EBITDA	15,130	20,439	19,861	20,070	18,014	21,265	20,542	23,000	19,737	10%	-14%
Margins (%)	24.0%	30.3%	28.9%	27.8%	25.4%	27.7%	25.6%	27.5%	23.2%		
Depreciation	3,031	3,583	3,790	3,770	3,712	3,810	3,975	4,719	4,555	23%	-3%
Other income	1,434	1,935	3,374	2,324	2,271	1,905	3,296	1,237	5,473	141%	342%
Interest	354	371	353	394	593	598	757	818	656	11%	-20%
PBT	13,179	18,420	19,092	18,230	15,980	18,762	19,106	18,700	19,999	25%	7%
Total tax	3,663	4,438	4,334	4,468	2,946	4,901	5,752	4,704	4,181		
Tax rate (%)	27.8%	24.1%	22.7%	24.5%	18.4%	26.1%	30.1%	25.2%	20.9%		
PAT before MI	9,516	13,982	14,758	13,762	13,034	13,861	13,354	13,996	15,818	21%	13%
Minority interest (MI)	76	43	42	27	35	59	-801	137	121		
Adj. PAT before extraordinary items	9,592	14,025	14,800	13,789	13,069	13,920	12,553	14,133	15,939	22%	13%
Extraordinary expenses	0	0	0	0	0	0	0	0	0		
Reported PAT	9,592	14,025	14,800	13,789	13,069	13,920	12,553	14,133	15,939	22%	13%
No. of shares	832.6	832.8	833.9	832.6	832.6	832.6	832.6	832.6	832.6		
EPS	11.5	16.8	17.7	16.5	15.7	16.7	15.1	17.0	19.1		

	file (%)										
(%)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25 Y	'-o-Y (bp) Q	-o-Q (bp
Margins (%)											
Gross	57%	59%	59%	58%	59%	60%	60%	59%	56%	-300	-312
EBITDA	24%	30%	29%	28%	25%	28%	26%	28%	23%	-223	-431
Adj.PAT	15%	21%	22%	19%	18%	18%	16%	17%	19%	29	183
Effective tax rate	28%	24%	23%	25%	18%	26%	30%	25%	21%	247	-425

(Rsm)	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	Y-o-Y (%)	Q-o-Q (%)
US formulations INR	25,321	31,978	31,700	33,492	32,626	38,462	37,281	33,834	35,586	9%	5%
% total revenue	40.2%	47.5%	46.1%	46.4%	46.1%	50.1%	46.5%	40.5%	41.8%		
Europe INR	4,960	5,071	5,286	4,970	5,208	5,265	5,770	12,096	12,750	145%	5%
% total revenue	7.9%	7.5%	7.7%	6.9%	7.4%	6.9%	7.2%	14.5%	15.0%		
Russia CIS INR	7,500	7,600	8,000	8,200	7,200	7,400	9,000	9,400	8,900	24%	-5%
% total revenue	11.9%	11.3%	11.6%	11.4%	10.2%	9.6%	11.2%	11.2%	10.5%		
India	12,834	11,482	11,860	11,800	11,265	13,252	13,971	13,464	13,047	16%	-3%
% total revenue	20.4%	17.0%	17.2%	16.4%	15.9%	17.3%	17.4%	16.1%	15.3%		
RoW	3,700	4,000	4,200	4,633	4,891	4,478	5,554	4,958	5,081	4%	2%
% total revenue	5.9%	5.9%	6.1%	6.4%	6.9%	5.8%	6.9%	5.9%	6.0%		
PSAI INR	7,787	6,709	7,034	7,839	8,219	7,657	8,407	8,219	9,563	16%	16%
% total revenue	12.4%	10.0%	10.2%	10.9%	11.6%	10.0%	10.5%	9.8%	11.2%		
Prop. products/ other	866	544	722	1,214	1,420	212	179	1,614	133	-91%	-92%
% total revenue	1.4%	0.8%	1.0%	1.7%	2.0%	0.3%	0.2%	1.9%	0.2%		
Total revenue	62,968	67,384	68,802	72,148	70,829	76,726	80,162	83,585	85,060	20%	2%


Figure 4: Actuals versus estimates					
	Actuals	Incred Estimates	Variance (%) Bloom	berg Estimates	Variance (%)
Revenue (Rsm)	85,060	85,555	-1%	83,694	2%
EBITDA (Rsm)	19,737	22,682	-13%	22,816	-13%
Margin (%)	23.2	26.5		27.3	
PAT (Rsm)	15,939	14,444	10%	14,657	9%
			SOURCE:	NCRED RESEARCH, C	OMPANY REPORTS

Figure 5: Our revised earnings estimates			
		FY26F	
	Old	New	Variance (%)
Revenue (Rsm)	3,49,031	3,54,680	2%
EBITDA (Rsm)	85,624	90,403	6%
Margin (%)	24.5	25.5	
PAT (Rsm)	53,638	57,598	7%
		SOURCE: INCRED RESEARCH,	COMPANY REPORTS

InCred Equities

Pharmaceuticals | India Dr Reddy's Laboratories Ltd | May 12, 2025






InCred Equities

Pharmaceuticals | India Dr Reddy's Laboratories Ltd | May 12, 2025

BY THE NUMBERS



Profit & Loss					
(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Total Net Revenues	245,879	279,163	325,535	354,680	331,089
Gross Profit	139,343	163,606	190,428	204,550	180,853
Operating EBITDA	63,873	78,384	84,544	90,403	79,097
Depreciation And Amortisation	(12,636)	(14,855)	(17,059)	(18,273)	(20,273)
Operating EBIT	51,237	63,529	67,485	72,130	58,824
Financial Income/(Expense)	(1,428)	(1,711)	(2,829)	(2,300)	(2,000)
Pretax Income/(Loss) from Assoc.					
Non-Operating Income/(Expense)	10,188	9,904	11,911	6,000	6,000
Profit Before Tax (pre-El)	59,997	71,722	76,567	75,830	62,824
Exceptional Items					
Pre-tax Profit	59,997	71,722	76,567	75,830	62,824
Taxation	(15,300)	(16,186)	(19,538)	(18,958)	(15,706)
Exceptional Income - post-tax					
Profit After Tax	44,697	55,536	57,029	56,873	47,118
Minority Interests	370	147	(484)	725	750
Preferred Dividends					
FX Gain/(Loss) - post tax					
Other Adjustments - post-tax					
Net Profit	45,067	55,683	56,545	57,598	47,868
Recurring Net Profit	45,067	55,683	56,545	57,598	47,868
Fully Diluted Recurring Net Profit	45,067	55,683	56,545	57,598	47,868

Cash Flow					
(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
EBITDA	63,873	78,384	84,544	90,403	79,097
Cash Flow from Invt. & Assoc.					
Change In Working Capital	(7,845)	(20,182)	(29,989)	(26,093)	11,309
(Incr)/Decr in Total Provisions					
Other Non-Cash (Income)/Expense					
Other Operating Cashflow	66,704	68,394	66,683	70,310	96,406
Net Interest (Paid)/Received	(1,428)	(1,711)	(2,829)	(2,300)	(2,000)
Tax Paid	(6,401)	(21,250)	(17,426)	(21,933)	(18,956)
Cashflow From Operations	58,875	45,433	46,428	46,078	75,450
Capex	(11,241)	(15,339)	(26,992)	(25,000)	(15,000)
Disposals Of FAs/subsidiaries					
Acq. Of Subsidiaries/investments			(53,413)		
Other Investing Cashflow	(7,543)	(11,032)	(6,894)		
Cash Flow From Investing	40,091	19,062	(40,871)	21,078	60,450
Debt Raised/(repaid)	(19,382)	5,493	24,490	(194)	(3,641)
Proceeds From Issue Of Shares	368	805	(1,196)		
Shares Repurchased					
Dividends Paid	(4,979)	(6,648)	(6,662)	(6,661)	(6,661)
Preferred Dividends					
Other Financing Cashflow	660	(102)	1,065	3,700	4,000
Cash Flow From Financing	(23,333)	(452)	17,697	(3,155)	(6,302)
Total Cash Generated	16,758	18,610	(23,174)	17,923	54,148
Free Cashflow To Equity	79,584	69,988	30,047	66,961	132,259
Free Cashflow To Firm	100,394	66,206	8,386	69,455	137,900

SOURCE: INCRED RESEARCH, COMPANY REPORTS

Pharmaceuticals | India Dr Reddy's Laboratories Ltd | May 12, 2025

BY THE NUMBERS...cont'd

(Rs mn)	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Total Cash And Equivalents	63,029	81,639	58,465	76,388	130,536
Total Debtors	72.485	80,298	90,420	102,857	96,016
Inventories	48,670	63,552	71,085	81,576	76,150
Total Other Current Assets	22,756	26.278	30,142	35,468	33,109
Total Current Assets	206,940	251,767	250,112	296,290	335,811
Fixed Assets	66,462	76,886	97,761	104,488	99,216
Total Investments	5,362	5,255	15,202	15,202	15,202
Intangible Assets	35,094	41,204	108,613	108,613	108,613
Total Other Non-Current Assets	7,996	12,406	21,301	21,301	21,301
Total Non-current Assets	114,914	135,751	242,877	249,604	244,332
Short-term Debt	12,194	14,030	38,902	38,902	38,902
Current Portion of Long-Term Debt	, -	,	,	,	,
Total Creditors	26,444	30,919	35,523	32,778	31,617
Other Current Liabilities	47,207	51,090	55,967	60,874	58,717
Total Current Liabilities	85,845	96,039	130,392	132,554	129,236
Total Long-term Debt	1,278	5,990	7,864	7,670	4,029
Hybrid Debt - Debt Component					
Total Other Non-Current Liabilities	3,740	4,939	17,567	17,567	17,567
Total Non-current Liabilities	5,018	10,929	25,431	25,237	21,596
Total Provisions					
Total Liabilities	90,863	106,968	155,823	157,791	150,832
Shareholders Equity	230,991	280,550	333,388	385,050	427,007
Minority Interests			3,778	3,053	2,303
Total Equity	230,991	280,550	337,166	388,103	429,310
Key Ratios					
	Mar-23A	Mar-24A	Mar-25A	Mar-26F	Mar-27F
Revenue Growth	14.7%	13.5%	16.6%	9.0%	(6.7%)
Operating EBITDA Growth	14.7% 38.7%	13.5% 22.7%	16.6% 7.9%	9.0% 6.9%	(6.7%) (12.5%)
Operating EBITDA Growth Operating EBITDA Margin	14.7% 38.7% 26.0%	13.5% 22.7% 28.1%	16.6% 7.9% 26.0%	9.0% 6.9% 25.5%	(6.7%) (12.5%) 23.9%
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs)	14.7% 38.7% 26.0% 59.46	13.5% 22.7% 28.1% 73.93	16.6% 7.9% 26.0% 14.04	9.0% 6.9% 25.5% 35.77	(6.7%) (12.5%) 23.9% 105.10
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs)	14.7% 38.7% 26.0% 59.46 277.13	13.5% 22.7% 28.1% 73.93 336.59	16.6% 7.9% 26.0% 14.04 399.99	9.0% 6.9% 25.5% 35.77 461.97	(6.7%) (12.5%) 23.9% 105.10 512.31
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover	14.7% 38.7% 26.0% 59.46 277.13 35.88	13.5% 22.7% 28.1% 73.93 336.59 37.13	16.6% 7.9% 26.0% 14.04 399.99 23.85	9.0% 6.9% 25.5% 35.77 461.97 31.36	(6.7%) (12.5%) 23.9% 105.10 512.31 29.41
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate	14.7% 38.7% 26.0% 59.46 277.13	13.5% 22.7% 28.1% 73.93 336.59	16.6% 7.9% 26.0% 14.04 399.99	9.0% 6.9% 25.5% 35.77 461.97	(6.7%) (12.5%) 23.9% 105.10 512.31
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5%	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6%	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5%	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0%	(6.7%) (12.5%) 23.9% 105.10 512.31 29.41 25.0%
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5% 103.36	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6% 99.88	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5% 95.71	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0% 99.45	(6.7%) (12.5%) 23.9% 105.10 512.31 29.41 25.0% 109.62
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5% 103.36 170.54	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6% 99.88 177.23	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5% 95.71 181.87	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0% 99.45 185.58	(6.7% (12.5% 23.9% 105.10 512.31 29.41 25.0% 109.62 191.60
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5% 103.36 170.54 89.11	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6% 99.88 177.23 90.59	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5% 95.71 181.87 89.75	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0% 99.45 185.58 83.03	(6.7% (12.5% 23.9% 105.1(512.3 29.4 25.0% 109.62 191.60 78.22
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days ROIC (%)	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5% 103.36 170.54 89.11 21.3%	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6% 99.88 177.23 90.59 21.7%	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5% 95.71 181.87 89.75 15.4%	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0% 99.45 185.58 83.03 15.0%	(6.7% (12.5% 23.9% 105.1(512.3° 29.4° 25.0% 109.6° 191.6° 78.2° 12.8%
Operating EBITDA Growth Operating EBITDA Margin Net Cash Per Share (Rs) BVPS (Rs) Gross Interest Cover Effective Tax Rate Net Dividend Payout Ratio Accounts Receivables Days Inventory Days Accounts Payables Days	14.7% 38.7% 26.0% 59.46 277.13 35.88 25.5% 103.36 170.54 89.11	13.5% 22.7% 28.1% 73.93 336.59 37.13 22.6% 99.88 177.23 90.59	16.6% 7.9% 26.0% 14.04 399.99 23.85 25.5% 95.71 181.87 89.75	9.0% 6.9% 25.5% 35.77 461.97 31.36 25.0% 99.45 185.58 83.03	(6.7%) (12.5%) 23.9% 105.10 512.31 29.41

SOURCE: INCRED RESEARCH, COMPANY REPORTS

DISCLAIMER

This report (including the views and opinions expressed therein, and the information comprised therein) has been prepared by Incred Research Services Private Ltd. (formerly known as Earnest Innovation Partners Private Limited) (hereinafter referred to as "IRSPL"). IRSPL is registered with SEBI as a Research Analyst vide Registration No. INH000011024. Pursuant to a trademark agreement, IRSPL has adopted "Incred Equities" as its trademark for use in this report.

The term "IRSPL" shall, unless the context otherwise requires, mean IRSPL and its affiliates, subsidiaries and related companies. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IRSPL and its affiliates/group companies to registration or licensing requirements within such jurisdictions.

This report is being supplied to you strictly on the basis that it will remain confidential. No part of this report may be (i) copied, photocopied, duplicated, stored or reproduced in any form by any means; or (ii) redistributed or passed on, directly or indirectly, to any other person in whole or in part, for any purpose without the prior written consent of IRSPL.

The information contained in this report is prepared from data believed to be correct and reliable at the time of issue of this report.

IRSPL is not required to issue regular reports on the subject matter of this report at any frequency and it may cease to do so or change the periodicity of reports at any time. IRSPL is not under any obligation to update this report in the event of a material change to the information contained in this report. IRSPL has not any and will not accept any, obligation to (i) check or ensure that the contents of this report remain current, reliable or relevant; (ii) ensure that the content of this report constitutes all the information a prospective investor may require; (iii) ensure the adequacy, accuracy, completeness, reliability or fairness of any views, opinions and information, and accordingly, IRSPL and its affiliates/group companies (and their respective directors, associates, connected persons and/or employees) shall not be liable in any manner whatsoever for any consequences (including but not limited to any direct, indirect or consequential losses, loss of profits and damages) of any reliance thereon or usage thereof.

Unless otherwise specified, this report is based upon reasonable sources. Such sources will, unless otherwise specified, for market data, be market data and prices available from the main stock exchange or market where the relevant security is listed, or, where appropriate, any other market. Information on the accounts and business of company(ies) will generally be based on published statements of the company(ies), information disseminated by regulatory information services, other publicly available information and information resulting from our research. While every effort is made to ensure that statements of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable as of the date of the document in which they are contained and must not be construed as a representation that the matters referred to therein will occur. Past performance is not a reliable indicator of future performance. The value of investments may go down as well as up and those investing may, depending on the investments in question, lose more than the initial investment. No report shall constitute an offer or an invitation by or on behalf of IRSPL and its affiliates/group companies to any person to buy or sell any investments.

The opinions expressed are based on information which is believed to be accurate and complete and obtained through reliable public or other nonconfidential sources at the time made (information barriers and other arrangements may be established, where necessary, to prevent conflicts of interests arising. However, the analyst(s) may receive compensation that is based on his/their coverage of company(ies) in the performance of his/their duties or the performance of his/their recommendations. In reviewing this report, an investor should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additional information is, subject to the duties of confidentiality, available on request. The report is not a "prospectus" as defined under Indian Law, including the Companies Act, 2013, and is not, and shall not be, approved by, or filed or registered with, any Indian regulator, including any Registrar of Companies in India, SEBI, any Indian stock exchange, or the Reserve Bank of India. No offer, or invitation to offer, or solicitation of subscription with respect to any such securities listed or proposed to be listed in India is being made, or intended to be made, to the public, or to any member or section of the public in India, through or pursuant to this report.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

The research analysts, strategists or economists principally responsible for the preparation of this research report are segregated from the other activities of IRSPL. Information barriers and other arrangements have been established, as required, to prevent any conflicts of interests.

IRSPL may have issued other reports (based on technical analysis, event specific, short-term views, etc.) that are inconsistent with and reach a different conclusion from the information presented in this report.

Holding of Analysts/Relatives of Analysts, IRSPL and Associates of IRSPL in the covered securities, as on the date of publishing of this report

Research Analyst or his/her relative(s) or InCred Research Services Private Limited or our associate may have any financial interest in the subject company.

Research Analyst or his/her relatives or InCred Research Services Limited or our associates may have actual or beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of the Research Report.

Research Analyst or his/her relative or InCred Research Services Private Limited or our associate entities may have any other material conflict of interest at the time of publication of the Research Report.

In the past 12 months, IRSPL or any of its associates may have:

- a) Received any compensation/other benefits from the subject company,
- b) Managed or co-managed public offering of securities for the subject company,
- c) Received compensation for investment banking or merchant banking or brokerage services from the subject company,
- d) Received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company

We or our associates may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.

Research Analyst may have served as director, officer, or employee in the subject company.

We or our research analyst may engage in market-making activity of the subject company.

Analyst declaration

- The analyst responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his
 or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and
 autonomously in an unbiased manner.
- No part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations(s) or view(s) in this report or based on any specific investment banking transaction.
- The analyst(s) has(have) not had any serious disciplinary action taken against him/her(them).
- The analyst, strategist, or economist does not have any material conflict of interest at the time of publication of this report.
- The analyst(s) has(have) received compensation based upon various factors, including quality, accuracy and value of research, overall firm performance, client feedback and competitive factors.

IRSPL and/or its affiliates and/or its Directors/employees may own or have positions in securities of the company(ies) covered in this report or any securities related thereto and may from time to time add to or dispose of, or may be materially interested in, any such securities.

IRSPL and/or its affiliates and/or its Directors/employees may do and seek to do business with the company(ies) covered in this research report and may from time to time (a) buy/sell the securities covered in this report, from time to time and/or (b) act as market maker or have assumed an underwriting commitment in securities of such company(ies), and/or (c) may sell them to or buy them from customers on a principal basis and/or (d) may also perform or seek to perform significant investment banking, advisory, underwriting or placement services for or relating to such company(ies) and/or (e) solicit such investment, advisory or other services from any entity mentioned in this report and/or (f) act as a lender/borrower to such company and may earn brokerage or other compensation. However, Analysts are forbidden to acquire, on their own account or hold securities (physical or uncertificated, including derivatives) of companies in respect of which they are compiling and producing financial recommendations or in the result of which they play a key part.

Registration granted by SEBI, membership of a SEBI recognized supervisory body (if any) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

InCred Research Services Private Limited Research Analyst SEBI Registration Number: INH000011024 Registered Office: Unit No 1203, 12th Floor, B Wing, The Capital, C-70, G Block, BKC, Bandra (E), Mumbai – 400051 Phone: +91-22-6844-6100 Corporate Office: 05th floor, Laxmi Towers, Plot No. C-25, G Block, Bandra – Kurla Complex, Bandra (East), Mumbai – 400051 Phone: +91-22-4161-1500 Name of the Compliance Officer: Mr. Yogesh Kadam Email ID: compliance@incredresearch.com, Phone No: +91-22-41611539 For any queries or grievances, you may contact the Grievance Officer. Name of the Grievance Officer: Mr. Rajarshi Maitra Phone no. +91-022-41611546 Email ID: rajarshi.maitra@incredresearch.com

CIN: U74999MH2016PTC287535

Pharmaceuticals | India Dr Reddy's Laboratories Ltd | May 12, 2025

Recommendation	Framework
Stock Ratings	Definition:
Add	The stock's total return is expected to exceed 10% over the next 12 months.
Hold	The stock's total return is expected to be between 0% and positive 10% over the next 12 months.
Reduce	The stock's total return is expected to fall below 0% or more over the next 12 months.
	return of a stock is defined as the sum of the: (i) percentage difference between the target price and the current price and (ii) the forward net be stock. Stock price targets have an investment horizon of 12 months.
Sector Ratings	Definition:
Overweight	An Overweight rating means stocks in the sector have, on a market cap-weighted basis, a positive absolute recommendation.
Neutral	A Neutral rating means stocks in the sector have, on a market cap-weighted basis, a neutral absolute recommendation.
Underweight	An Underweight rating means stocks in the sector have, on a market cap-weighted basis, a negative absolute recommendation.
Country Ratings	Definition:
Overweight	An Overweight rating means investors should be positioned with an above-market weight in this country relative to benchmark.
Neutral	A Neutral rating means investors should be positioned with a neutral weight in this country relative to benchmark.
Underweight	An Underweight rating means investors should be positioned with a below-market weight in this country relative to benchmark.